TLSITLSIHealthcare · Medical Devices

TLSI Stock Forecast: TriSalus Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.32
+6.67% on the day

The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. hold a median 12-month price target of $6 — +158.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$143.1M
Ticker Nerd rank
34/ 100
Median analyst target
$6.00
Analysts covering
4
Revenue$11.4M+1.7% y/y
Operating income−$9.8M
Net income−$9.2M
Free cash flow−$10.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.5%
1M
−36.6%
YTD
−66.8%
1Y
−53.2%
From 52W high
−69.1%
From 52W low
+6.7%
$2.18
$7.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores TriSalus Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
34/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Quality
55
Momentum
43
Issuance
41
Volatility
40
Value
37
Revisions
25
Accruals
23

Growth (79): Sales and profits are climbing, and climbing faster than before.

Accruals (23): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26TLSIHigh $14.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$4.00
Low
$6.00
Median
$14.00
High

The green dot is the last close — the median target sits +158.6% from it.

Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
11 Nov 2026Canaccord GenuityMaintainsBuy$7.00 → $4.00
11 Nov 2026HC Wainwright & Co.MaintainsBuy$12 → $10
23 Sept 2026HC Wainwright & Co.MaintainsBuy$11 → $12
9 Sept 2026HC Wainwright & Co.InitiatesBuy$11
13 May 2026Lake StreetMaintainsBuy$10 → $8.00
9 Mar 2026Canaccord GenuityMaintainsBuy—
6 Mar 2026Canaccord GenuityMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
28 Mar 2025Canaccord GenuityMaintainsBuy—
13 Feb 2025Lake StreetInitiatesBuy—
24 Jan 2025Roth MKMReiteratesBuy—
17 Dec 2024Cantor FitzgeraldInitiatesOverweight—
15 Nov 2024Canaccord GenuityMaintainsBuy—
11 Nov 2024Roth MKMInitiatesBuy—
25 Oct 2024Northland Capital MarketsInitiatesOutperform—
16 Sept 2024OppenheimerInitiatesOutperform—
27 June 2024Canaccord GenuityMaintainsBuy—
30 May 2024Canaccord GenuityInitiatesBuy—
10 May 2024JonesTradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TLSI.

Market Radar

This page is one stock. Monday covers all of them.

TLSI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TLSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, TriSalus Life Sciences, Inc. returned −53.2% against +6.9% for the S&P 500, dividends included.

TLSI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26TLSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.1×

Cheaper than 36% of US stocks

Price / book
210.9×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
86.8%

Higher than 95% of US stocks

Operating margin
−63.0%

Higher than 17% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−38.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TriSalus Life Sciences, Inc. has a market value of $143.1M and an enterprise value of $135.8M.

  • Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 1.7% year on year.

  • Net income over the same four quarters: −$28.2M, a −62.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.30.

  • Free cash flow in the twelve months to 30 June 2026: −$23.3M.

  • Shares outstanding: 61.5M.

  • TriSalus Life Sciences, Inc. employs 102 people — $442K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

TLSI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TLSITriSalus Life Sciences, Inc.$143.1M34
INGNInogen, Inc.$144.3M77
MXCTMaxCyte, Inc.$146.8M94
LUNGPulmonx Corp.$111.9M87
RXSTRxSight, Inc.$185.0M54
APYXApyx Medical Corp.$101.1M76
ELMDElectromed, Inc.$191.7M89

Take a look at TLSI’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own TriSalus Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TLSI

What is the TLSI stock price forecast for 2026-2027?

The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSI stock a buy right now?

Of the 4 analysts covering TriSalus Life Sciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TriSalus Life Sciences, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSI?

As at 21 Nov 2026, TriSalus Life Sciences, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will TLSI stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +158.6% from the last close, and Ticker Nerd's factor model ranks TriSalus Life Sciences, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSI stock forecast for 2030?

No analyst covering TriSalus Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $14 over the next 12 months.

How has TLSI stock performed over the past year?

TriSalus Life Sciences, Inc. returned -53.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device.

Company

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.

CEO Ms. Mary T. Szela B.S.N., M.B.A. · 102 employees · United States · https://trisaluslifesci.com